Opendata, web and dolomites

CONTRA SIGNED

Computational ONcology TRaining Alliance

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CONTRA project word cloud

Explore the words cloud of the CONTRA project. It provides you a very rough idea of what is the project "CONTRA" about.

rendering    joined    complemented    patients    25    recruitment    commercial    struggle    consequently    evolution    suffering    rectify    fortunately    heterogeneity    biotech    train    social    unleash    analysing    employments    unprecedented    survival    genomic    contra    evolutionary    lie    components    sequencing    assaying    biomarker    thereby    single    durable    pharmaceutical    death    forces    complementary    scheme    training    collectively    researched    esrs    15    teach    drug    substantial    academic    mathematical    computational    techniques    subsequently    diagnosis    molecular    opportunity    excellent    industrial    begun    industry    geographical    biology    frequently    huge    insights    nevertheless    skills    initially    tumour    successful    combination    posed    force    cancer    security    medical    expertise    software    spatial    innovative    entrepreneurship    cell    intersection    data    somatic    last    modern    situation    tackle    genders    treatment    fail    public   

Project "CONTRA" data sheet

The following table provides information about the project.

Coordinator
KUNGLIGA TEKNISKA HOEGSKOLAN 

Organization address
address: BRINELLVAGEN 8
city: STOCKHOLM
postcode: 100 44
website: www.kth.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 3˙863˙978 €
 EC max contribution 3˙863˙978 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2017
 Funding Scheme MSCA-ITN-ETN
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KUNGLIGA TEKNISKA HOEGSKOLAN SE (STOCKHOLM) coordinator 527˙318.00
2    KING'S COLLEGE LONDON UK (LONDON) participant 546˙575.00
3    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 546˙575.00
4    EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH CH (ZUERICH) participant 530˙453.00
5    FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) ES (BARCELONA) participant 495˙745.00
6    UNIVERSIDAD DE VIGO ES (VIGO PONTEVEDRA) participant 495˙745.00
7    UNIWERSYTET WARSZAWSKI PL (WARSZAWA) participant 448˙274.00
8    THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL UK (LONDON) participant 273˙287.00
9    Ardigen SA PL (Kraków) partner 0.00
10    British Columbia Cancer Agency Branch CA (Vancouver) partner 0.00
11    FUNDACION CENTRO TECNOLOXICO DE TELECOMUNICACIONS DE GALICIA ES (VIGO) partner 0.00
12    Merck KGaA DE (DARMSTADT) partner 0.00
13    Seven Bridges Genomics UK Limited UK (LONDON) partner 0.00
14    Spatial Transcriptomics AB SE (Solna) partner 0.00
15    TORUS SOFTWARE SOLUTIONS S.L. ES (A CORUNA) partner 0.00

Map

 Project objective

Cancer is a major cause of death and suffering, rendering it a huge concern to the general public. Consequently, it has been targeted by application of the molecular techniques developed during the last 20-25 years, thereby improving diagnosis and treatment. Nevertheless, although current biomarker and treatment concepts often are successful initially, they subsequently frequently fail to achieve durable drug response and long-term survival for cancer patients. The study of somatic evolution in cancer is a very promising approach to rectify this situation. Fortunately, single cell genomic sequencing has recently begun to provide opportunity to unprecedented detailed insights into tumour evolution and new techniques are emerging for assaying the spatial distribution of tumour heterogeneity. Analysing and developing methods for these emerging data sets are under-researched areas that lie at the intersection of medical, evolutionary biology, and computational research. In CONTRA, European researchers with complementary expertise have joined forces in order to collectively facilitate training of future European computational cancer researchers. We will by applying modern recruitment and selection methods in combination with offering excellent training and employments conditions, including social security, facilitate recruitment of 15 excellent ESRs, across genders and geographical areas. We will train these 15 ESRs in the mathematical, computational, and applied skills required to tackle the complex analysis problems posed by somatic evolution in cancer. We will also teach them entrepreneurship and the requirements of pharmaceutical and biotech industry. Using a novel scheme, this substantial academic cancer expertise will be complemented with industrial expertise in software development, especially for biotech and pharmaceutical industry, which will unleash key components of the innovative force of the European commercial sector in the struggle against cancer.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CONTRA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CONTRA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

EAGRE (2020)

Eagre/Aegir: high-seas wave-impact modelling

Read More  

GREAT (2019)

Grating Reflectors Enabled laser Applications and Training

Read More  

SuperCol (2020)

SuperCol: Rational design of super-selective and responsive colloidal particles for biomedical applications

Read More